Poxviral-based vaccine against severe acute respiratory syndrome coronavirus 2 and methods using the same
AssigneeAcademia Sinica
InventorsWen Chang, Rakesh Kulkarni, Shiu-Lok Hu
Life of this patent
Estimating the term…
Abstract
The present invention relates to a recombinant poxviral vector for use in vaccinating a subject against SARS-CoV-2. The present invention also provides vaccination regimens using the recombinant poxviral vector, which confers protective immunity against SARS-CoV-2.
Claims30
A recombinant poxviral vector which comprises a polynucleotide encoding a SARS-CoV-2 spike protein in a poxviral vector for use in vaccinating a subject against SARS-CoV-2.
An immunogenic composition against SARS-CoV-2 which comprises an effective amount of a recombinant poxviral vector and a physiologically acceptable vehicle, wherein the recombinant poxviral vector comprises a polynucleotide encoding a SARS-CoV-2 spike protein in a poxviral vector.
A method for vaccinating a subject against SARS-CoV-2, comprising administering to the subject an effective amount of a recombinant poxviral vector or an immunogenic composition comprising the recombinant poxviral vector, wherein the recombinant poxviral vector comprises a polynucleotide encoding a SARS-CoV-2 spike protein in a poxviral vector.
Dependencies are inferred from the claim text.